ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

5 Insightful Analyst Questions From Colgate-Palmolive’s Q3 Earnings Call

CL Cover Image

Colgate-Palmolive’s third quarter results reflected a stable but challenging consumer environment, as the company delivered sales in line with Wall Street expectations and non-GAAP profit that modestly exceeded consensus. CEO Noel Wallace cited persistent headwinds including consumer uncertainty, cost inflation, and heightened promotional activity as pressures on sales and profit growth. Management attributed the flat organic sales and declining volumes primarily to ongoing sluggishness in North America and category softness in developed markets, while highlighting sequential improvement in performance outside of skin health. Wallace noted, “We are operating with determination and focus,” pointing to broad-based market share stability and continued investment in advertising and innovation as critical to navigating the current landscape.

Is now the time to buy CL? Find out in our full research report (it’s free for active Edge members).

Colgate-Palmolive (CL) Q3 CY2025 Highlights:

  • Revenue: $5.13 billion vs analyst estimates of $5.14 billion (1.9% year-on-year growth, in line)
  • Adjusted EPS: $0.91 vs analyst estimates of $0.89 (2.4% beat)
  • Adjusted EBITDA: $1.22 billion vs analyst estimates of $1.22 billion (23.7% margin, in line)
  • Operating Margin: 20.6%, in line with the same quarter last year
  • Organic Revenue was flat year on year vs analyst estimates of 1.3% growth (89.3 basis point miss)
  • Sales Volumes fell 1.9% year on year (3.7% in the same quarter last year)
  • Market Capitalization: $62.28 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Colgate-Palmolive’s Q3 Earnings Call

  • Dara Mohsenian (Morgan Stanley) asked about the duration of category softness and the timeline for Colgate-Palmolive’s strategic initiatives to drive organic sales growth. CEO Noel Wallace responded that sluggishness is expected in the near term, but initiatives under the 2030 Strategy are designed to stimulate growth regardless of category trends.
  • Peter Grom (UBS) questioned the impact of the Colgate Total formula change in Latin America and whether growth in the region would improve. Wallace detailed the consumer-driven formula adjustment and expressed confidence in market share recovery as the new product is adopted.
  • Filippo Falorni (Citi) explored the effects of India’s GST change and local competition. Wallace explained that the tax reduction caused short-term disruption but is expected to boost category consumption over time, with a renewed focus on premiumization in urban areas.
  • Lauren Lieberman (Barclays) inquired about the sustainability of pricing in Europe. Wallace said positive pricing should continue but could be challenged by prolonged inflation, underscoring the role of innovation in maintaining premium positioning.
  • Stephen Powers (Deutsche Bank) asked how Colgate’s investments in AI and innovation differentiate it versus peers and whether they are points of competitive advantage. Wallace emphasized that technology and process improvements are being deployed to gain a market edge and drive category growth with retailers.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be monitoring (1) the pace at which the new Colgate Total formula regains market share in Latin America, (2) the effectiveness of science-based innovation and AI-driven marketing in driving demand across premium and value segments, and (3) the progression of the strategic growth and productivity program in delivering cost savings and operational improvements. Continued supply chain optimization and the impact of pricing actions will also be key areas of focus.

Colgate-Palmolive currently trades at $77.50, up from $76.51 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.10
+0.00 (0.00%)
AAPL  275.25
+0.00 (0.00%)
AMD  237.52
+0.00 (0.00%)
BAC  53.63
+0.00 (0.00%)
GOOG  291.74
+0.00 (0.00%)
META  627.08
+0.00 (0.00%)
MSFT  508.68
+0.00 (0.00%)
NVDA  193.16
+0.00 (0.00%)
ORCL  236.15
+0.00 (0.00%)
TSLA  439.62
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.